1. COVID-19: Consigli FISMAD per l’assistenza ai pazienti con malattie dell’apparato digerente e per gli operatori sanitari in Gastroenterologia – Revisione 1 (02.04.2020). https://fismad.it/wp-content/uploads/2020/04/FISMAD_COVID19_REV01_ita.pdf (accesso il 30-04-2020)
2. National Health Committee of the People’s Republic of China, National Administration of Traditional Chinese Medicine. Diagnostic and therapeutic guidance for 2019 novel coronavirus disease (version 5). Available from:http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a/files/ab6bec7f93e64e7f998d802991203cd6.pdf
3. Reid G. Can bacteria help humans fight COVID-19? post 17 March 2020,https://naturemicrobiologycommunity.nature.com/channels/2549-coronaviruses-past-present-and- future/posts/62121-can-bacteria-help-humans-fight-coronavirus
4. Conti P et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020 Mar 14;34(2).
5. Chen L et al. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 6;43(0):E005
6. Drago L et al. Colonizzazione intestinale di Lactobacillus casei subsp. Casei I-1572 CNCM (L. casei DG) in volontari sani e in topi germ-free. Farmaci & terapia 2002; 19 (1/2): 72-76
7. Ferrario C et al. Modulation of Fecal Clostridiales Bacteria and Butyrate by Probiotic Intervention with Lactobacillus paracasei DG Varies among Healthy Adults. J Nutr 2014; 144 (11): 1787-96
8. Arioli S et al. Quantitative Recovery of Viable Lactobacillus paracasei CNCM I-1572 (L. casei DG®) After Gastrointestinal Passage in Healthy Adults. Front Microbiol. 2018; 9:1720 (9 pages).
9. Altaha et al. Detection Probiotic’s DNA of Lactobacillus paracasei in Healthy Human Faeces. Journal of Pharmaceutical Research International 2018; 23(6): 1-9,
10. Radicioni M et al. Survival of L. casei DG® (Lactobacillus paracasei CNCMI1572) in the gastrointestinal tract of a healthy paediatric population. Eur J Nutr. 2019; 58(8):3161-3170
11. Cremon C et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United European Gastroenterol J. 2018; 6(4): 604-613